Tumors release components such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and tumor-derived extracellular vesicles into the circulation. Multiple studies have demonstrated that molecular information about tumors and metastases can be extracted from these factors, which are therefore frequently referred to as "liquid biopsies." Liquid biopsies allow the longitudinal monitoring of tumor genomes non-invasively and may hence ensure that patients receive appropriate treatments that target the molecular features of their disease. Accordingly, the number of studies employing liquid biopsy based assays has been skyrocketing in the last few years. Here, we focus on three important issues, which are of high relevance for monitoring tumor genomes. First, we analyze the relation between the allele frequency of somatic tumor-specific mutations and the tumor fraction within plasma DNA. Second, we ask how well current tumor evolution models correlate with findings in longitudinal liquid biopsy studies. And, finally, as sensitivity is one of the key challenges of mutation detection, we address the challenge of detecting mutations occurring at very low allele frequencies in plasma DNA.
Precision medicine describes the selection of targeted therapies based on an improved understanding of the genetic basis of disease. 1 This has important implications in oncology, because with the increasing feasibility of sequencing tumor genomes, a genome-driven oncology may evolve to a standard in the clinical management of patients with cancer. 2, 3 However, it has been questioned whether precision oncology will indeed produce long-lasting remission and extend survival. 4, 5 One of the possible reasons why the concepts of precision oncology are considered as unproven by some 4 may be the enormous biological and clinical complexity of such a genome-driven oncology, which includes that genomes of cancer cells are usually unstable and that they may constantly acquire novel changes under selection pressures such as given therapies. Hence, in order to realize precision medicine in oncology the evolution of tumor genomes needs to be constantly monitored by longitudinal sampling. However, tissue biopsies, which require invasive procedures, cannot be obtained at multiple time points. In contrast, "liquid biopsies" refer to procedures analyzing parts of tumors, which have been shed into the blood, such as circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), or tumor-derived extracellular vesicles. As these components can be obtained simply by a blood draw, that is, non-invasively or minimallyinvasively, respectively, they can be easily acquired at multiple time points. Indeed, the field of liquid biopsy-based analyses is rapidly evolving. Publication activities for the last thirty years (i.e., 1986-2016) based on PubMed ( Fig. 1) indicate that CTCs have already been investigated intensively for several decades, whereas circulating exosomes represent a relatively novel area of investigation. A number of factors, such as the aforementioned promises of precision medicine, the emergence of novel technologies allowing completely new options to study circulating tumor components, such as next-generation sequencing (NGS), the ongoing search for prognostic and predictive biomarkers, the prospect of unraveling factors involved in tumor dissemination and metastases, all may have contributed to the sharp increase in interest and publication activities for all three liquid biopsy components in recent years ( Fig. 1) . As the field is so rapidly evolving, review articles on this topic are being published almost on a weekly basis. Here, we list just a few recent comprehensive reviews, which were published on CTCs, [6] [7] [8] [9] [10] [11] [12] ctDNA, 7, 10, 11, [13] [14] [15] [16] [17] [18] [19] and exosomes or extracellular vesicles, respectively, 14, [20] [21] [22] and which covered most relevant aspects of these relatively novel technologies. In the light of this large number of excellent published reviews, we will focus here on aspects mainly of ctDNA analyses, which have not been covered in the aforementioned reviews yet to avoid replication and redundancies. Our own previous work focused on assessing and evaluation of somatic copy number changes (SCNAs), as well as mutations from CTCs and ctDNA. 16, [23] [24] [25] [26] [27] [28] [29] As analyses of ctDNA are emerging as a promising tool to monitor the clinical course of patients with cancer and to follow the evolution of cancer genomes, that is, by evaluating response to treatment or by assessing the emergence of drug resistance, we will focus on the following issues in this review: First, how well does the mutant allele frequency (MAF) of somatic tumor-specific mutations indeed reflect the tumor fraction within plasma DNA? Second, how well do current tumor evolution models correlate with findings in longitudinal liquid biopsy studies? And finally, as sensitivity level is one of the key challenges of mutation detection, how well can we detect mutations occurring at very low allele frequencies?
Mutant Allele Frequency (MAF) and Tumor Fraction
A plethora of approaches to detect mutations in plasma DNA ranging from the focused analysis of a single mutation to panel sequencing to whole-exome sequencing have been described. 24, 28, [30] [31] [32] [33] [34] [35] [36] [37] Metrics to quantify ctDNA include the mutant allele fraction (percentage of mutated DNA copies of the respective region in plasma DNA) and the mutant allele concentration (absolute number of mutated DNA copies per milliliter). The measured allele frequency of the detected mutation is frequently equated with the percentage of tumor fraction in plasma DNA. However, this is an oversimplification, as the MAF depends on the ploidy of the tumor and the SCNA status of the gene where the mutation is located. We illustrate this deliberation for diploid ( Fig. 2a) as well as for triploid (Fig. 2b ) tumors. These model calculations illustrate both somatic and germline mutations and the copy number status of the respective region. Several conclusions can be drawn from these calculations: First, the MAF would reflect the true tumor fraction within plasma DNA only if the same somatic mutation in a diploid tumor genome was present on both chromosomes [i.e., in case of a copy number neutral loss of heterozygosity (LOH)], in case of a triploid tumor, if the mutation is on two chromosomes and the chromosome with the wild type allele is lost. Second, depending on the ploidy and SCNA status, the MAF can vary widely, for example, for a true tumor fraction of 50% from 0.20 to 0.50. Third, the MAF may change from one measurement to the next independently of the percentage of the tumor fraction if the SCNA status of the respective region changes. Fourth, tumor fraction should be estimated for several mutations simultaneously, and these mutations should be located in regions with different SCNA status. Finally, the MAFs for germline mutations can also be affected by SCNAs in the tumor genome, but usually to a much lesser extend. This information can be used to facilitate the distinction between germline and somatic mutations. For example, for plasma samples with a tumor fraction below 30% (which is the case in the vast majority of cases) somatic mutations can be distinguished from germline mutations with ease, because the germline MAF will always be above 30% (Fig. 2c) .
In addition, MAFs can be affected by biological factors. Amounts of circulating DNA originating from non-cancerous cells may be highly variable, for example, due to inflammatory process, and mask high MAFs of somatic mutations. Mutations may change due to the impact of chemotherapy and, as plasma DNA represents a kind of average of the mutational patterns from various anatomical locations, the MAFs also depend on the ctDNA release from individual sites and the tumor cell heterogeneity. Moreover, measured MAF values may deviate from expected MAFs due to chance. For example, in a pure tumor DNA sample, that is, 100% tumor DNA, a heterozygous mutation should have a MAF of 50%. However, calculation of MAFs using random numbers from a binomial distribution demonstrate that using a 100x coverage MAFs may lie in fact between 40 and 62 and a similar MAF variability will be obtained for all tumor fractions (Fig. 2d) .
The copy number status is usually represented as a log 2 -ratio. For example, in a pure (i.e., 100%) diploid tumor cell population a balanced region has a log 2 -ratio of 0 [2/2 5 1; log 2 1 5 0], a heterozygous deletion a log 2 -ratio of 21 [1/ 2 5 0.5; log 2 (0.5) 5 21], a trisomy a log 2 -ratio of 0.585 [3/ 2 5 1.5; log 2 (1.5) 5 0.585], and so on. However, when calculating SCNAs from plasma DNA such values will never be reached due to the inevitable and always-present dilution with DNA released from non-cancer cells in blood. In Figure  2 , it is also depicted how the log 2 -ratios change depending on the tumor fraction within the plasma DNA. Tumor fractions can also be estimated based on sophisticated SCNA measurements, for example, with the ABSOLUTE algorithm, 38 which estimates tumor purity and ploidy from observed relative copy number profiles and which can also be applied to plasma DNA. 39 A special case are focal amplifications, which will often have highly increased log 2 -ratios due to their high copy number even when the tumor fraction is low (Fig. 2e ).
Current Tumor Evolution Models and Longitudinal Liquid Biopsy Studies
The aforementioned considerations stress the importance that MAFs have frequently to be interpreted within the context of ploidy and SCNA patterns of the primary tumor and/ or metastases shedding DNA fragments into the circulation. This raises the question whether there is a strong likelihood that SCNA patterns may frequently change or whether they are relatively stable. An equally important question is the evolution of mutations in tumor genomes, which may be also affected by given therapies. This is further complicated by the observation that the clonal mutation burden may already have accumulated prior to carcinogenesis in some cancers, whereas in others mutation burden may reflect somatic events occurring after tumorigenesis. 40 However, an important feature of liquid biopsies is the option to develop longitudinal sampling strategies. As tumors appear to have multiple evolutionary capabilities, liquid biopsies may contribute to an improved understanding of these evolutionary trajectories.
The sequential cancer gene hypothesis predicts that cancers emerge from normal cells through sequential mutations in tumor driver genes, that is, oncogenes or tumor suppressor genes. 41 Indeed, in cancer types with well-defined precancerous and cancerous lesions, such as melanoma, pancreatic, cervical, or colon carcinoma, the initial steps in tumorigenesis were divided into three phases, that is, breakthrough phase, expansion phase, and invasive phase, which are each governed by mutations in relatively specific driver genes. 42 Indeed, in at least some tumor entities a sequence of 3 mutations may be sufficient for the development of cancer. 42, 43 However, additional mutations develop and contribute to the tremendous genetic heterogeneity, which has been observed in many human cancers 44 and it is a matter of debate how tumors accumulate point mutations and SCNAs. A gradual accumulation of point mutations has been referred to as "micro-evolution," whereas the evolution of large-scale chromosomal alterations has been dubbed "macroevolution." 45 In general, the biological process by which a tumor expands to form its mass can be distinguished into several tumor evolution processes, that is, linear, branching, neutral, or punctuated evolution. 46 Linear evolution corresponds to the aforementioned sequential cancer gene hypothesis and describes a process where new driver mutations provide a selective advantage strong enough to outcompete previous clones. This implies the presence of a major dominant clone. The first and classical linear evolution model is the one suggested by Fearon and Vogelstein for patients with colorectal cancer. 47 Such a linear evolution model may be of particular relevance in very early stages of tumor progression, whereas there is less evidence for linear evolution in advanced carcinomas. 46 In any case, as tumors following a linear evolution model develop gradually, they are unlikely to show a tremendous number of novel changes (SCNAs as well as mutations) from one ctDNA analysis to the next (Fig. 3a) .
Branching evolution involves the co-existence of several subclones that may expand in parallel and that are-in contrast to linear evolution-not outcompeted by selective sweeps 46 ( Fig. 3b) . This evolution is common in many cancers as evidenced by numerous NGS studies (as reviewed by Ref. 44 ). Accordingly, mutations can be truncal, that is, they occur in all clones, or subclonal, that is, they have evolved from the trunk of the phylogenetic tree and are observed only in a distinct lineage. Importantly, tumors following branching evolution are characterized by ongoing clonal evolution so that established driver mutations may not only be observed in trunks but also in branches, that is, in subclones. 44, 46 At the same time the distributions of temporally and spatially different clones may shift under selection pressures. Diversity of clones may contribute to selection of aggressive subclones in both presence or absence of therapeutic selection pressures. 44 Branching evolution is consistent with clonal diversification 48 and the transition from an adenocarcinoma to a neuroendocrine prostate carcinoma represents an impressive example detected by ctDNA analyses where a different clone takes over. 28 In such cases the clonal shift is characterized by the loss of the clone with Branching evolution involves the co-existence of several subclones that may expand in parallel and that are -in contrast to linear evolution-not outcompeted by selective sweeps. Hence, in tumors following branching evolution significant changes may be observed in liquid biopsies if one clone expands at the expense of other clones. (c) Punctuated evolution refers to a process where a large number of genomic aberrations may occur in short bursts of time, usually at very early stages of tumor progression. A punctuated evolution model would predict relatively stable SCNA patterns; however, novel mutations may occur. (d) In cancer cells there may be a variable cell-to-cell number of ecDNA (extrachromosomal DNA). As a consequence, tumor cells releasing their DNA into the circulation may have different copy numbers of the ecDNA, whereas all other SCNAs should show a stable pattern. Hence, amplifications caused by ecDNA may differ in their amplitude from one analysis to the next, whereas amplifications due to HSRs should show stable amplitude. The evolution models shown on the left side in a-c were adapted from. 46 [Color figure can be viewed at wileyonlinelibrary.com]
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amplification of the androgen receptor (AR), which also explains why these patients develop complete androgen receptor independence at this disease stage. Instead, another clone, which frequently has a very different SCNA pattern, evolves. 28, 49 Hence, in tumors following branching evolution multiple significant changes may be observed in liquid biopsies in relatively short order of longitudinal analyses (Fig. 3b) .
Punctuated evolution refers to a process where a large number of genomic aberrations may occur in short bursts of time, usually at very early stages of tumor progression 46 (Fig.  3c) . Whereas linear and branching evolutions are mainly supported by point mutations, evidence for punctuated evolution was provided by SCNAs and chromosomal structural rearrangements in patients with breast and colorectal carcinomas. [50] [51] [52] As diversity occurs very early in tumor evolution, this model was also named "big bang theory" and subsequent intratumor heterogeneity development was suggested to follow rather the laws of neutral growth, that is, novel changes in the tumor genome have no functional significance on tumor proliferation. 51 A recent study has indeed found evidence for neutral growth patterns in a number of tumors. 53 Hence, a punctuated evolution model would predict relatively stable SCNA patterns; however, novel mutations may occur (Fig. 3c) .
Hence, some evolution models (i.e., linear and punctuated evolutions) would predict relatively stable SCNA patterns over time, which would be consistent with earlier notions about the existence of selected, stable aneuploidy karyotypes that have evolved to support maximal proliferation and in which the stresses caused by aneuploidy karyotypes are suppressed. 54 This also reinforces that aneuploidy cannot be equated with chromosomal instability. 55 In contrast, the branching evolution is compatible with changing SCNA patterns through clonal diversification. However, the evolution models may also undergo a transition from one model to another. A strength of liquid biopsies is that these models can now be tested with appropriate longitudinal analyses.
Focal Amplifications as a Rapid Adaption Mechanism in Cancer Cells
Focal amplifications represent a special scenario not addressed by the aforementioned evolution models. There is no exact definition to describe focal amplifications. To classify "focal amplifications" we have implemented a more stringent definition than used in other studies, [56] [57] [58] that is, the amplicon size should be smaller than 20 Mb, with a log 2 -ratio > 0.2 and 0.2 higher than adjacent segments, and we excluded regions with >100 genes, >50% segmental duplications or overlap with known Database of Genomic Variants. 28, 59 Such a stringent definition for focal amplifications has likely biological significance, because recently it has been shown that amplified genes can reside either within chromosomes [often referred to as homogenously staining regions (HSRs)], or as extrachromosomal DNA (ecDNA). 60 In fact, ecDNA was found to be common in cancer cells, and furthermore, that their number significantly varies from cell to cell. The ecDNA should be of biological significance, as they often contained oncogenes, which showed high expression levels. ecDNA copy numbers increase intratumor heterogeneity and it was suggested that this mechanism enables a rapid adaption of tumor cells to changing environmental conditions. 60 This model implies an interesting challenge to ctDNA analyses: the variable cell-to-cell number of ecDNA is in part due to unequal segregation to daughter cells. As a consequence, tumor cells releasing their DNA into the circulation may have highly variable copy numbers of the ecDNA, whereas all other chromosomal segments affected by SCNAs should show a stable pattern (Fig. 3d) . Hence, amplifications caused by ecDNA may differ in their amplitude from one analysis to the next, whereas amplifications due to HSRs should show stable amplitude. It should be highly interesting to test whether such phenomena will be indeed observed with serial ctDNA analyses.
In any case, focal amplifications may represent a flexible and rapid mean for cancer cells to novel selection pressures. Indeed, we have recently shown that focal amplifications are a driving force in patients with metastatic prostate cancer, and furthermore, that the mean time interval between novel occurring amplifications was about 26 weeks in this tumor entity. 28 
Detection of Mutations Occurring with Low-Allele Frequency
The various evolution models with their intratumor heterogeneity require the detection of mutations, in cases of metastatic disease from various anatomical sites, which may each occur with low allele frequency. The same applies of course to the detection of minimal residual disease, which is another aim of liquid biopsy approaches. Furthermore, sensitivity level is one of the key challenges of mutation detection methods and the limit of detection is the threshold below which mutations cannot be discriminated from background noise.
Cell free DNA (cfDNA) is a mixture of DNA from tumor cells (i.e., the ctDNA) and non-cancer cells. Depending on the tumor fraction, somatic mutations may be present in cfDNA at very low allele frequencies (Fig. 2) . Furthermore, a typical plasma sample of 1 ml contains approximately 3,000 copies of each gene, implicating a sensitivity limit of detecting only 1 in 15,000 copies from a 5 ml sample. 61 Including statistical sampling errors, the available genome equivalents of clinical samples will be an important determinant of possible resolution limits in ctDNA analyses.
Due to these limited amounts of cfDNA in most cases a higher number of PCR cycles needs to be performed in order to get sufficient amounts of library fragments for subsequent sequencing. Error rates and fidelity for sequencing and PCR are well documented [62] [63] [64] and background errors were shown to be increasingly evident below allele fractions of 0.2% and under an allele fraction of 0.02% in >50% of sequenced genomic positions, artefacts are present. 65 In general, increased sensitivity of assays for ctDNA can be achieved by (i) the development of new or modified polymerases with reduced error rates and (ii) the use of more template molecules per assay, (iii) digital approaches and/or (iv) sophisticated bioinformatics approaches.
Digital approaches refer to technologies where DNA templates are diluted to a degree that individual molecules are separately amplified and analyzed. As a consequence, each individual analysis will be either completely mutant or completely wild type. 66 In order to increase the output of digital PCR, different formats such as microfluidics or solid phase PCR have been introduced. 67 However, as all these systems still have relatively high error rates, molecular barcoding as "an ultimate form of digital PCR" 67 has been established. 68 These barcoding methods add a degenerated tag consisting of several random basepairs (UMI, unique molecular identifier) to each template molecule, thereby enabling the precise tracking of individual molecules after PCR amplification and, at the same time, a reduction of the false positive rate to at least 15 to 24-fold. [68] [69] [70] During the analysis sequencing reads with the same UMI are combined to read groups (UMI families) and a consensus sequence is generated. Mutations are only considered as true if they are present in the majority of read group members. Several variations of the incorporation of molecular barcodes, including molecular barcodes in the ligation adapters 
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during the library construction step for genome sequencing, have been developed, 65, 70 in target-specific PCR primer 68 and in molecular inversion probes for targeted somatic mutation detection. 71 Despite the achievement of error suppression, these approaches also encounter some challenges. First and most importantly, the original template molecules are not uniformly amplified and therefore not all template molecules are recovered as UMI families. In fact, a substantial proportion of read groups may contain <5 read group members, and often only 1 or 2 reads form a UMI family. As examples we illustrate the UMI family member distribution for some currently used barcoding technologies, that is, the SafeSequencing System (Safe-SeqS), 68 and the commercially available NEBNext Direct V R Cancer HotSpot Panel and the ThruPLEX V R Tag-seq Kit (Fig. 4) . As error suppression is not feasible in these groups, they might be discarded in the final analysis depending on the analysis strategy. Additionally, uneven amplification might result in UMI families with several hundreds of read group members. Together, these issues lead to a massive reduction of the sequencing depth, and therefore a sufficient depth for rare variant calling requires much more sequencing capacity compared to conventional sequencing. A more even target recovery might be achieved by lowering the input amount, which in turn leads to a decreased limit of detection as sensitivity is dictated by the number of input molecules. However, the variant calling sensitivity is positively correlated with the amount of the input DNA and, moreover, sampling biases must also be taken into account. For example, a recent study employing a multiplex amplicon barcoding protocol has shown that only 6% (on average 208 copies) of input copies were recovered after sequencing 10 ng of human DNA. 72 Therefore, increasing the efficiency to form full amplicons during initial steps is essential for detecting DNA variants at low fractions when the input is limited. In addition PCR efficiency is relatively inefficient when limited amounts of input DNA are used-as it is most likely the case for cfDNA-resulting in primer/adapter dimers. 73 To sum up, in order to correctly identify MAF for specific mutations, tremendous technological efforts, for example, digital PCR systems employing molecular barcodes and bioinformatics approaches 33, 37, 65, 68, 70 for amplification/sequencing error suppression, have been developed. In the light of these developments, it is surprising that the impact of SCNAs and ploidy level of the primary tumor and its metastases on allele frequency (Fig. 2) has not been appreciated to a comparable extent yet. Hence, despite the proven potential of barcoding to detect low allele frequency mutations, tremendous challenges for their accurate detection remain.
Conclusions
One of the exciting options of liquid biopsies -beside disease monitoring-represents the opportunity to confirm currently discussed tumor evolution models. Results could include data consistent with linear, punctuated, or branched tumor evolution, or observations that different models may occur concurrently or whether they may shift from one model to the next. Liquid biopsies may even identify novel trajectories of tumor evolution. Plasma DNA analyses should be ideally suited to assess such diversity and models, because SCNAs and MAFs in plasma are averages from various tumor sites, which release tumor DNA into the circulation. 35 Methods analyzing SCNA patterns genome-wide, such as plasma-Seq, 26 may reveal relatively stable aneuploid karyotypes, which withstand selection pressures over long periods of time. However, tumors following a branching evolution may differ from such stable tumors, because clonal diversification may contribute to significant alterations in the ctDNA composition from one measurement to the next. 28, 49 Thus, even in cancers developing according to linear or punctuated evolution, it would be highly interesting to catalogue and map new "small changes," that is, gains or losses of chromosomal segments, which may occur during tumor evolution. Among such "small changes," novel focal amplifications may be an intriguing example, as they may have a great impact on the disease course. 28, 59 Future directions will include the extraction of further information from plasma DNA, such as epigenetic data. For example, the tissue of origin of plasma DNA can be established by "plasma DNA tissue mapping," an approach employing genome-wide bisulfite sequencing of plasma DNA and methylation deconvolution of the sequencing data. 74 The signal-to-noise ratio of such approaches can be increased by using stretches of several adjacent CpG sites as tissue-specific methylation markers. 75, 76 Furthermore, a direct association between cfDNA and nucleosome positioning was demonstrated. 77 In addition, nucleosome positions inferred from whole-genome sequencing of plasma DNA showed distinct read-depth patterns at transcription start sites and allowed conclusions about the expression status of the respective genes. 39 However, one of the biggest challenges for future cfDNA applications will be to elucidate the underlying biology of DNA release into the circulation. For example, has ctDNA an over-representation of DNA from dying tumor cells, as plasma DNA is closely linked to DNA released from apoptotic cells 32, 39, 77, 78 and, if so, how can liquid biopsies reflect the active disease status? What additional factors, that is, from microenvironment or immune factors contribute to the DNA release? Toll-like receptor 9 (TLR9) is an endosomal sensor for DNA 79 and a link between cfDNA, inflammatory disease and TLR9 has recently been reported. 80 These and other questions to understand the biology of ctDNA release will have to be answered if cfDNA analyses should really advance to an indispensable diagnostic tool in the management of patients with cancer.
